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Peptoids as Transcription Factor Mimics to Target the Coactivator Med25 
Protein-protein interactions (PPIs) play significant roles in all cellular activities. The interactions 
are guided by cellular signals which direct how and where these proteins assemble. The 
information encoded by DNA is transcribed, for example, as a result of complex PPI networks 
formed by dynamic transcriptional proteins. If any of the PPIs malfunction, then the resulting 
dysregulation leads to human diseases such as cancer, neurodegenerative disorders, developmental 
disorders, and abnormal metabolic activities.  
At the core of the transcriptional PPI network are proteins known as transcriptional 
activators that bind to specific sequences of DNA. The other basic component of activators is the 
transcriptional activator domain (TAD), which functions to recruit coactivators in the process of 
assembling the transcription machinery. Coactivators play a key role in transcriptional regulation 
as they serve to interact with multiple protein partners, including activators. The complexes formed 
between activators and coactivators have modest affinity and are often transient in nature, since 
they are formed as part of the assembly/disassembly part of the transcriptional machine. 
Additionally, coactivators use binding sites with large surface areas to form PPIs with activators 
and other binding partners. This aids the recruitment of the RNA polymerase following the 
interactions of these classes of proteins. 
Typically, small molecules tend to be most potent when they act as ligand for proteins such 
as enzymes that have deeper grooves and small surface areas. However, coactivator proteins have 
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large surface areas and produce moderate affinities when interacting with binding partners. 
Because of these characteristics, it has been challenging using small molecules to target these 
interactions. In the case of the target coactivator for this study, Med25, the domain that interacts 
with activators has two 900 Å2 binding surfaces that are intractable for small molecule ligands. 
Med25 is dysregulated in many human diseases and there is thus a strong need to identify synthetic 
modulators that would be useful for mechanistic studies.  
Towards this end, we first identified minimal binding sequences from known 
transcriptional activators that interact with  the Activator Interaction Domain (AcID). The 
information gleaned from these studies presented the opportunity to develop synthetic ligands of 
Med25 AcID using peptidomimetics based on those sequences. Peptoids were chosen as the 
scaffold due to their ability to resist proteolytic degradation, cover large surface areas and present 
diverse functional groups as sidechains. We demonstrated that we could design peptoids based on 
identified minimal peptides that interact with Med25 AcID to recapitulate binding to the Med25. 
After optimization, the best peptoid exhibited low micromolar affinity for Med25 AcID and good 
selectivity against a related coactivator.   
The work yielded promising results leading us to improve the compounds so that that they 
have intercellular applications. Cell penetrating peptides were appended to the optimal peptoid and 
the cell permeability assessed by visualizing  Vari-068 cells, a triple-negative  breast cancer cell 
line, treated with fluorescently-labeled variants of the peptoid. One version could be seen 
throughout the cell, including the nucleus, after 6 hours. Taken together, this work demonstrates 
xi 
 
that we can design mimics of native TADs to interact with larger surface areas with moderate 









Protein-protein interactions play a significant role in maintaining cellular processes in cells. These 
are complex networks involving numerous proteins interacting with each other in a transient 
fashion. One of the essential functions of cellular systems is transcription, which is a process in 
which genetic information is regulated. This involves key proteins such as transcriptional 
activators, which at a minimum comprise a DNA binding domain (DBD), that binds to a specific 
DNA sequence and transcriptional activation domain (TAD) that recruits coactivators to the DNA 
transcription site. The coactivator interacts with the TAD with its Activator Binding Domain 
(ABD) as it helps to assemble the other components of the transcription machinery such as the 
RNA polymerase II enzyme. Misregulation of activator-coactivator complexes contributes to a 
wide range of human diseases. As a result, these complexes are attractive therapeutic targets. One 
of the most common techniques for targeting activator-coactivator PPIs is discovery of small 
molecule ligands. However, due to the large surface areas of the PPIs these molecules are often 
incapable of being effective modulators as they are incapable of covering large surface areas. Here, 
we propose using peptidomimetics as a strategy that could address the limitations of small 
molecules as they possess diverse chemical structures, can interact with large binding surfaces, 




1.2 Transcriptional Activator-Coactivator Complexes 
Protein-protein interactions (PPIs) are essential for biological systems to function, and, as a result 
PPIs are tightly regulated by preprogrammed cellular signals.1 An example of a functionally 
important class of PPIs are those formed between transcriptional activators and coactivators in the 
earliest step of gene transcription. Transcriptional activators recognize particular sequences in the 
promoter regions of genes in a signal-responsive fashion and then form short-lived PPIs with 
transcriptional coactivators to initiate formation of the transcriptional machinery.2,3 At the core of 
this multiprotein network is the RNA polymerase II (Pol II), which is the central enzyme in the 
transcriptional machine.2,4,5 The well-characterized protein family ETV/PEA3 includes examples 
of transcriptional activators that form PPIs with the coactivator protein Med25; ETV/PEAS-
Med25 complexes lead to the recruitment of the Mediator complex to genes such as MMP-1, 
stimulating transcription.  
Figure 1.1 Transcriptional Machinery Assembly. Activator-coactivator complexes facilitate assembly of the 
transcriptional machinery in a signal-responsive fashion. Transcriptional activators are often held by masking proteins 
(MP) in inactive form until needed. A signal, often in the form of a post-translational modification, causes the masking 
protein-activator interaction to change. The DNA binding domain (DBD, deep blue) of the activator localizes the 
activator to particular sites in the genome. The transcriptional activation domain (TAD, red) then forms PPIs with 
coactivators to stimulate formation of the transcriptional machine.  
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Misregulation of activator-coactivator PPIs, not surprisingly, results in myriad diseases such as 
autoimmune diseases, cancers, neurological degenerative and cardiovascular diseases to name a 
few.6–14 To ameliorate situations arising from misregulation of activator•coactivator complexes, it 
is important to understand the mechanism(s) through which these molecules function. 
Transcriptional activators are minimally composed of a DNA-binding domain that localizes the 
protein to particular sites within a genome and a transcriptional activation domain, or TAD, that 
forms complexes with coactivators.15–18 Activators are often classified based upon the sequence of 
their TAD, falling into the category of amphipathic/acid-rich, glutamine-rich, or proline-rich. The 
largest class is that of the amphipathic group, in which the TAD sequences are (as the name 
suggests) comprised of hydrophobic residues that are interspersed with polar amino acids, often 
glutamic or aspartic acid.3,19–22 
 
TADs commonly interact with two classes of proteins. One class comprises masking proteins, and 
the well-studied tumor suppressor and transcriptional activator p53 and its masking protein partner 
MDM2 are an excellent example.23–26  Another example is the yeast transcription factor Gal4 and 
Figure 1.2. TADs interact with coactivator protein. The CBP/p300 KIX domain interacts 
with several TADs using both of its binding sites. The TADs represent examples of 
diseases in which they are implicated. 
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its binding partner Gal80 masking protein-TAD PPI.23,24 Typically, masking proteins bind with 
high affinity to activator partners, with dissociation constants in the low nanomolar range.24 
Conversely, TADs interact with coactivators, the second class of binding partners, with low to 
moderate affinities (micromolar to high nanomolar dissociation constants).25 TADs are diverse in 
size as they range from a few amino acids to over 100 amino acids in length. Some activators such 
as VP16 and p53 have multiple TAD domains that allow them to interact independently with other 
proteins.26–32 
A remarkable feature of transcriptional activators and their coactivator binding partners is that they 
are hub proteins, using a single domain to interact with many different binding partners. The TAD 
within the yeast activator Gal4, for example, interacts with more than 10 different  
coactivators.33–36  The hub domains within coactivators are called activator-binding domains or 
ABDs. Some coactivators such as cAMP-response element binding protein (CREB-binding 
protein – CBP) contain multiple ABDs. The CBP ABD KIX interacts with CREB, MLL, c-Jun, c-
Myb and p53 along with other proteins (Figure 1.2).37 A similar KIX domain in the Mediator 




As noted above, the complexes formed between transcriptional activators and their coactivator 
binding partners are implicated in a number of diseases. This can be due to up- or down-regulation 
of one or both binding partners, altered signaling pathways, or mutations/deletions/translocations 
of the transcription factor. For example, in a subset of AML, chromosomal translocation of the 
transcriptional activator MLL leads to loss of function, contributing to leukomogenesis.43–45 In an 
example relevant to this dissertation, the ETV/PEA3 transcriptional activators are up-regulated in 
a number of cancers (Figure 1.3).44,46–49 Table 1 illustrates  further examples of misregulated 
transcription factors and cancer and other diseases are highlighted.  
 
 
Figure 1.3 ETV/PEA3 activators. a) The three ETV family members have nearly identical transcriptional activation 
domains.50  b) Although all three ETV family members are considered to be oncogenes, there is considerable evidence 
for activation of ETV1 and ETV4 inducing invasion and migration programs through several mechanisms. There is 
less data for ETV5 but The cancer Genome Atlas (TCGA) database analysis reveals that it is in the top 1% amplified 





Transcriptional Activator Result of Misregulation 
TAL-1 T cell acute lymphoblastic leukemia 
c-Myb hematopoietic malignancies/breast cancer 
ETV-1 Early prostate cancer 
ETV-5 Head & Neck cancer 
ETV-4 Prostate cancer 
FoxO-3 Degenerative disorder 
P53 Cancer, DNA damage 





XBP-1 Neurodegenerative disease 
RUNX-2 Developmental disorder 
MLL Acute myelogenous leukemia 
 
HIF1-a Cancer (solid tumors) 
 
Table 1: Examples of transcription and the consequences of misregulation. These transcriptional activators are 
involved in a complex network of protein-protein interactions with coactivators and other proteins. If there are any 
anomalies in the formation of the PPIs, the result can lead to diseases.7  
 
As noted in Figure 1.3, a group of particularly exciting activator•coactivator complexes are those 
formed between the ETV/PEA3 activators and the coactivator Med25. The ETV activators regulate 
the transcriptional status of their cognate genes through a direct interaction between their 
transcriptional activation domains and the coactivator Med25.54–56 More specifically, the Activator 
Interaction Domain (AcID) of Med25 is the target of the ETV activators, with a KD of ~500 nM.57  
Med25 is anchored to the Mediator complex via its VWA domain and formation of the ETV-
Med25 AcID complex leads to recruitment of Mediator to promoters, a critical step in assembly 
of the transcriptional pre-initiation complex.58 Overexpression of the Med25 AcID or the VWA 
domain inhibits ETV-mediated transcription. In triple-negative breast cancer cells, for example, 
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overexpression of AcID led to down-regulation of metastasis-associated genes such as matrix 
metalloproteases, as did shRNA knockdown of ETV1, 4 and 5; importantly, the most effective 
inhibition was observed when all three ETV activators were knocked down.54 Taken together, the 
hypothesis that emerges from these data is that a synthetic inhibitor of the Med25-ETV complex 
would block key metastasis pathway and, as a result, be effective mechanistic probes for defining 
the role(s) of the ETV/PEA3 transcription factors in the metastatic transformation. However, as 




Figure 1.4 Med25 AcID is the critical binding partner for ETV/PEAs and other activators. a) The domains and 
function of Med25. b) Solution structure of Med25 AcID in complex with the transcriptional activation domain 
of VP16(413-490) (not shown). Highlighted residues indicate the predicted activator binding sites, with dark blue 
and maize colors indicating residues that shift significantly upon addition of VP16.(11) The blue site is termed 
the H1 binding surface as it interacts with the amino terminal residues of VP16 while the maize site is the H2 
surface, targeted by the C-terminus of VP16. Figure derived from PDB 2L23. 
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1.3 Activator•Coactivator Complexes are Considered ‘Undruggable’ 
Activator•coactivator complexes have long been deemed ‘undruggable’ because of their 
undesirable biophysical characteristics.59–62 As noted above, they typically are modest in affinity 
and transient. Additionally, they typically occur over large surface areas, ranging from 700-2000 
Å2 unlike enzyme active sites with an average surface area between 300 and 500 Å2 (Figure 1.5). 
 
Figure 1.5: Chemical space of protein-protein interactions. Some PPIs exist in the high affinity-small surface area, 
low affinity small surface area, high affinity large surface area, or the low affinity-large surface area space. Examples 
of these proteins are shown in each of these spaces.  
Previous work by former co-worker Dr. Steve Sturlis with the VP16(438-454) - Med25 AcID 
complex illustrates that the coactivator Med25 has a large binding surface, rather than one or more 
binding ‘hot spots’ (Figure 1.6). Replacement of each of the amino acids within the VP16 sequence 
with alanine and measurement of the binding affinity for Med25 revealed that the binding energy 
is spread over a large surface area, rather than localized to a few specific residues. As discussed in 
later sections, this is consistent with the challenge of identifying small molecule binders of 
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coactivators such as Med25 as small molecules typically do not have the array of functional groups 
needed for effective binding.63 
 
Figure 1.6: Alanine scan of VP16 (438-454). The Direct binding was measured for the peptide against Med25 Acid. 
This shows that binding is spread over a large surface area. Experiments were conducted by Dr. Steve Sturlis. 
 
In addition to the large surface area and modest affinity of activator-coactivator complexes posing 
a challenge for inhibitor discovery, both the individual binding partners and the resulting 
complexes are structurally highly dynamic. Transcriptional activation domains are unstructured 
prior to binding and the activator-binding domains within coactivators exist in numerous 
conformations (Figure 1.7). There is little high resolution structural data of activator-coactivator 
complexes, and, as a result, structure-based design strategies are ineffective.  
An additional challenge associated with ‘drugging’ activator•coactivator  complexes is that with 
transcription taking place in the nucleus, inhibitors must be not just cell permeable but also traffic 
to the nucleus.64 The cell membrane serves not just as a barrier to contain the components of the 
cell, but also poses a great challenge to efficiently delivering potent inhibitors of transcription. 
Native chemical elements of the cell membrane dictate what compounds it permits to pass through. 
The phospholipid bilayer would repel drug molecules that are negatively charged thus defeating 
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any hope for targeting transcription. Modulating the PPIs of activators and coactivators often 
mimics the amphipathic activators involved the in complex formation. In targeting the 
coactivators, the amphipathic molecule must successfully cross the membrane after introducing it 
to the biological system; however, this will be repelled upon interaction with the negatively 
charged phosphate heads of the membrane. For all of the reasons discussed in this section, 
activator-coactivator complexes have historically considered ‘undruggable’.59 
 
Figure 1.7. Protein adopts helical conformation upon interaction with target protein. PPIs are highly dynamic, thus 
posing as a great challenge for designing structure-based PPIs 
. 
1.4 Small Molecule Modulators of Activator•Coactivator PPIs 
Despite the challenges outlined in the previous section, there has been a great deal of effort devoted 
to identifying small-molecule inhibitors of activator-coactivator targets as mechanistic probes and 




Figure 1.8: Examples of small molecules inhibitors of the KIX activator-binding domain found in CBP/p300, 
ARC105, SREBP and other coactivtors. KIX domains, like other coactivator motifs, are tough to target due to 
conformational dynamics. Thus, although a number of potential inhibitors have been identified they all have modest 
to poor affinity for the their target, KIX.  
 
One of the most investigated coactivator targets is the master coactivator CPB/p300. Within that 
multi-domain coactivator is the KIX activator-binding domain (Figure 1.2, Figure 1.8) that through 
its interactions with the Myb and MLL transcriptional activators regulates hematopoiesis. The 
ternary Myb-KIX-MLL complexes is frequently dysregulated in acute myeloid leukemias (AML) 
and genetic and pharmacological studies have shown that disruption of KIX is sufficient to block 
leukemogenesis. Additionally, the PPI formed with the transcriptional activator CREB plays a 
prominent role in certain cancers as well as in neuropathic pain. For these reasons, multiple small 
molecule libraries have been screened against the KIX domain to identify inhibitors and design 
strategies have also been attempted.65   
Med15/Arc105 KIX CBP KIX Med15 KIX (yeast) 
K
D
 115 M 
PNAS 2004, 101, 17622; 
Bioorg Med Chem Lett  
2012, 20, 6811 
K
D
 1 mM 






 >200 M 
Mol Cancer Ther. 2013, 12, 1515;  
ACS Med Chem. Lett. 2012, 3, 30;  
ACS Chem. Biol. 2009, 4, 335;  
J. Am. Chem. Soc. 2007, 129, 10654. 
K
D
 740 M 
ChemBioChem 2018, 9, 963  
  Nature 2016, 1–5  
IC
50
  192 M 
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One of the earliest compounds to achieve success in targeting activator-coactivator interactions is 
the 2-naphthol-AS-E-phosphate (top left structure, Figure 1.8). This compound was identified 
from a drug discovery screen with over 700 compounds, and has been shown to bind specifically 
at a binding interface between CREB-CBP binding complex. Through a series of HSQC NMR 
experiments, the residues responsible for participating in the interaction were identified and further 
provided information for the most critical residue in the interaction. This surface that interacts with 
CREB also interacts with other proteins such Myb despite differing binding mechanisms, thus 
creating an opportunity to investigate whether the inhibitor has the ability to function specifically 
or broadly. Later results have illustrated that 2-naphthol-AS-Ephosphate is more a more potent 
inhibitor of Myb-CBP interaction compared to the CREB-CBP complex.  Nonetheless, even after 
optimization, the KD for KIX remains poor, 115 mM. Further, the selectivity of the molecule for 
CBP/p300 KIX over other coactivators (even other KIX domains) has not been established.4,5,22 
Several synthetic KIX ligands demonstrated that they can inhibit transcriptional activators such as 
Myb and MLL, which bind to opposite faces of the KIX domain of CBP. For example, small 
molecule inhibitors for KIX identified from library screening include depsides (Sekikaic acid) and 
depsidones (lobaric acid) (Figure 1.9). These molecules successfully inhibited the MLL binding 
surface of KIX, thus underscoring the ability to use of the small molecules to target coactivators 
and show some specificity for a particular surface of the targeted protein despite the challenges. 




Figure 1.9: Library screening identified small molecule inhibitors of activator coactivator PPI. Sekikacic acid and 
Lobaric acid have been identified as two of the more potent  inhibitors of activator-coactivator interactions.  
 
The coactivator that is the focus of this thesis, Med25, has also been a target of interest. It was 
demonstrated that Med25 AcID-activator complexes are able to be disrupted, like KIX-activator 
complexes, using natural products. Norstictic acid, psoromic acid and garcinolic acid were 
identified as effective inhibitors of the PPIs of Med25 AcID, which could potentially be used to 
inhibit transcription activation of genes regulated by the Med25 protein network.  Co-workers Dr. 
Steve Sturlis, Dr. Paul Bruno and Julie Garlick identified norstictic acid from two different screens 
of a complex between Med25 AcID and the activator ERM. It is a covalent inhibitor that binds to 
a loop on the H2 face of Med25 and in doing so inhibits complex formation at both the H1 and H2 
face with low micromolar apparent IC50 values in vitro and in cells. A related structure, psoromic 
acid, shows similar activity. Norstictic acid also shows excellent selectivity (5-100-fold) for 
Med25 AcID over all coactivators tested. As in the KIX examples, however, due to the structural 
complexes of norstictic acid and psoromic acid, further optimization has not been possible. 
sekikaic acid lobaric acid 
Ki
 




   
 
 
Figure 1.10: Natural products identified as inhibitors for activator-Med25 AcID complexes. These natural product 
inhibitors have shown to be potent inhibitors of TAD-Med25 AcID interactions. 
 
The examples above show that it is possible to identify inhibitors, even selective inhibitors, of 
activator-coactivator complexes. However, the most successful inhibitors are natural products with 
structural complexities that prevent further optimization. Co-workers in the Mapp lab and other 
groups have attempted to identify more drug-like scaffolds for KIX, Med25, and other 
coactivators. In the case of Med25, for example, former co-workers Dr. Steve Sturlis and Dr. Paul 
Bruno screened all 150,000 small molecules in the Center for Chemical Genomics collection and 
obtained not a single hit. Co-worker Julie Garlick has screened focused libraries from the 
University of Illinois and from AtomWise, again with no success. Given these results, our focus 
shifted to developing peptidomimetics that could be based on the amino acid sequences of 
transcriptional activators. The advantage would be the synthetic ease with which the size and 
psoromic acid norstictic acid 
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complexity of peptidomimetics can be tailored and, specifically, we chose peptoids as the 
peptidomimetic scaffold on which to focus. 
1.5 Peptoids as Protein Ligands and PPI Inhibitors  
Peptoids were first reported in the 1980s as modular peptidomimetics. Like peptides, individual 
peptoid monomers are connected through amide bonds that can be formed via solid-phase 
synthesis. What distinguishes peptoids is that the side chain of each monomer is on the nitrogen, 
rather than on the a-carbon as in peptides, leading to a-chiral molecules and the ability to install a 
wide range of functional groups during the synthesis (Figure 1.11). By the early 1990s peptoid 
pioneer Ronald Zuckerman along with others had developed many peptoids with improved 
pharmacokinetics compared to their peptide counterparts and with a variety of applications.66,67  
Because peptoids can be synthesized using automated strategies, the ease with which libraries can 
be prepared lead to screening approaches to identify protein-protein interaction inhibitors. An early 
example yielded one of the first peptoid ligands with a high affinity for 7-transmembrane G 
protein-coupled receptors. The identification of CHIR 2279 binding to α1-adrenoreceptors with a 
low nanomolar Ki proved that it was possible to develop a peptidomimetic library and successfully 





Figure 1.11: Comparison of peptide and peptoid structures. Peptoids mimic peptides with the substitution on the 
nitrogen atom instead of the alpha carbon. 
 
The Src homology 3 domains are frequently found in eukaryotic signaling proteins and thus are 
important targets for PPI inhibitors. These proteins are attractive targets as they are implicated in 
diseases such as cancer and degenerative diseases. They make contact with their target proteins 
via proline-rich regions of the targets. Jack Nguyen and colleagues developed a hybrid peptide-
peptoid library of molecules to improve selectivity. A library was developed with peptides and 
peptide-peptoid library and screened to identify potent binding ligands. The characteristics of 
peptoids were leveraged by substituting at least one amino acid in some sequences, which resulted 
in an improvement in affinity by 100-fold and specificity by 300-fold.  These hybrids illustrate 
that incorporating peptoids in a canonical motif can remedy the challenge of designing potent 
inhibitors of protein-protein interactions.  
A third example of peptoids working to modify PPI networks is in the realm of transcriptional 
PPIs. p53 is transcriptional activator that is regulated by associating with masking protein MDM2 
in normal cells. However, upon abnormal cellular functioning such as cellular stress or genomic 
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damage, it performs its transcriptional tasks to regulate transcription by binding to many proteins 
including coactivator proteins such as CBP/p300 and PC4 to regulate the cell cycle.69–72 Toshiaki 
Hara and colleagues demonstrated the successful design of a peptoid that inhibits the association 
of p53 with its binding partner MDM2. They were able to identify a peptoid with comparable 
affinity for the masking protein as the native p53 peptide. In another example, Kodadek and co-
workers carried out a screen of a peptoid library against the transcriptional coactivator Med15 and 
in doing so identified a number of short (7-residue) peptoids with micromolar affinity for the 
coactivator. Also, peptoids stability exceeds that of peptides In vivo due to their ability to withstand 
proteolytic degradation, withstand denaturants have shown to not produce anti-immune 
response.73–75  Taken together, these examples indicate that peptoids are a good scaffold for 
developing ligands of Med25 and, in the future, modulators of the Med25 PPI network.76,77 
 
1.5. Dissertation Summary 
The overall goal of this thesis is to develop peptidomimetics that can inhibit native protein-protein 
interactions between activators and coactivators. In these studies, we use Med25 AcID as our 
model to garner key insights into the engagement mechanism between Med25 AcID and its 
binding partners. Med25 AcID functions primarily as the key domain of coactivator Med25 
subunit that allows the protein to interact with activators. Because a number of the activator 
proteins that interact with Med25 are implicated in multiple diseases, synthetic ligands would have 
high value as mechanistic probes. We hypothesize that we can leverage the characteristics of 




In Chapter Two we show that Med25 has two discrete binding faces that selectively bind to the 
activators ERM and ATF6a. Additionally, truncation studies of the Med25-dependent activator 
VP16 were used to identify minimal peptide sequences needed for Med25 binding. Through  The 
work described in Chapter Three demonstrated that we could identify minimal sequences with 
good affinity for Med25 and optimize the peptoids to identify a structure with low micromolar 
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Coactivator Med25 Contains Two Binding Surfaces Targetable by Minimal Activator 
Sequences1 
2.1 Abstract 
Transcriptional coactivators are a molecular recognition marvel because a single domain within these 
proteins, the activator binding domain or ABD, interacts with multiple compositionally diverse 
transcriptional activators to regulate transcription. Also remarkable is the structural diversity among ABDs, 
which range from conformationally dynamic helical motifs to those with a stable core such as a -barrel. 
A significant objective is to define properties of ABD•activator complexes that allow them to be targeted 
by inhibitors. The ABD of the coactivator Med25 (Activator Interaction Domain or AcID) is unique in that 
it contains secondary structural elements that are on both ends of the spectrum: helices and loops that 
display significant conformational mobility and a seven-stranded -barrel core that is structurally rigid.  
Here, we use protein NMR and mutational analysis to identify the binding surfaces used by the natural 
activators ERM and ATF6α for complex formation. We further find that a minimal 8-residue sequence 
from the transcriptional activator binding partners is sufficient for binding. Taken together, these data 
indicate that modulating the Med25 PPI network should be possible using mimetics of the core 
transcriptional activation domain sequences.  
 
1 Portions of this chapter are taken from “Conservation of coactivator engagement mechanism 
enables small-molecule allosteric modulators” A. R. Henderson, M.J. Henley, N. J. Foster, A.L. 
Peiffer, M.S. Beyersdorf, K.D. Stanford, S. M. Sturlis, B. M. Linhares, Z.B. Hill, J. A. Wells, T. 





Modulating the protein-protein interactions (PPIs) formed between activator binding domains 
(ABDs) of transcriptional coactivators and their cognate activator binding partners is a formidable 
task and the reasons are revealed by biophysical studies of these functionally critical complexes.1 
An excellent example of this is the ABD of the Mediator protein Med25, termed AcID (Activator 
Interaction Domain; Figure 1A).2–4 As is standard for ABDs, AcID is a binding partner of a diverse 
array of transcriptional activators, including VP16, ATF6α,5 and the ETV/PEA3 activators.6,7 
Through these interactions, Med25 plays significant roles in the unfolded protein response and in 
oncogenesis, generating significant interest in small molecule modulators. However, data from 
NMR studies of AcID in complex with VP16 and ETV/PEA3 activators suggest that modulating 
these PPIs would not be trivial.2–4  The VP16 transcriptional activation domain contacts a surface 
of approximately 1800 Å2 of AcID, wrapping around the topologically challenging β-barrel while 
also contacting two flanking helices. The transcriptional activation domain of the ETV/PEA3 
member ERM interacts with one face of the β-barrel, a binding surface referred to as H1 that is 
~900 Å2 in area.6,7 The β-barrel core of AcID is highly unusual among ABDs, with helices more 
commonly observed, and raises the question of the role that the barrel might play in the molecular 




Figure 2.1: Med25 AcID with transcriptional activators (A) The AcID is the binding partner of a growing number of 
transcriptional activators and contains at least two binding surfaces, termed H1 and H2. The sequences of the 
transcriptional activation domains of the three Med25-dependent activators used in this study are shown below the 
protein structure (PDB ID code 2XNF) (B) Equilibrium dissociation constants for each of. Med25 AcID–activator 
complexes, measured through fluorescence anisotropy experiments using fluorescein-labeled peptides. These values 
are the average of at least three independent measurements with the error indicated (standard deviation of the mean). 
Binding measurements were completed by Dr. Andrew Henderson and Dr. Matthew Henley. 
 
 
The observation that a portion of VP16 and ERM utilize the same H1 binding surface in AcID 
despite their distinct sequences suggests that conformational plasticity within the ABD could play 
a role in its molecular recognition capabilities and ultimately function, similar to helical 
coactivators.  Indeed, computational, and biophysical studies of Med25 and its complexes by our 
group demonstrate that Med25 recognizes its partners via a mechanism analogous to that of helical 
coactivators, in which the loops and helices flanking the β-barrel play a role in molecular 
recognition.8 Remaining questions about Med25-activator complexes included identifying the 
binding site for the native partner ATF6α and the determination of the minimal binding sequences. 
Through mutational analysis I find that, analogous to helical coactivators, a minimal 8-residue 
sequence from activators is sufficient for interaction with Med25. Taken together, these results 
indicate that, despite its structural uniqueness, Med25 uses a similar molecular recognition 
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mechanism to complex with transcriptional activators. This sets the stage for inhibitor 
development based upon the native transcriptional activation domains. 
 
 
Figure 2.2: VP16 TAD has two coactivator binding domains: the N-terminal half of the VP16 transcriptional 
activation domain (red; H1 domain)  and the C- terminal region (green; H2 domain) are capable of independently 
stimulating transcription when associated with DNA.9,10 11 
 
2.3 Results and Discussion 
Separate NMR studies of AcID in complex with the transcriptional activation domains of VP16 
and ERM suggest that the two activators both contact the H1 binding surface, with the significantly 
larger VP16 also interacting with the H2 surface.2–4  While several lines of evidence indicate that 
ATF6α interacts with Med25 AcID as part of its function,5 the binding site within the protein had 
not been established. We first measured the dissociation constants for each of the activators by 
fluorescence anisotropy experiments using fluorescein-tagged variants of VP16(438-490), 
ERM(38-68) and ATF6α(40-66) and this revealed that ERM and ATF6α interact with comparable 
affinities (Figure 1.1B).2–6 To provide a direct comparison of the binding modes of the three 
activators and identify the binding site of ATF6α, we measured the chemical shift changes in each 
activator-AcID complex via 1H, 15N-HSQC NMR titration experiments, with VP16(438-490), 
ERM(38-68) and ATF6α(40-66) in the presence of 15N-labeled Med25 AcID.  
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The amide proton perturbation patterns measured for the activator•AcID complexes suggest a 
different binding mode for each of the three activators. VP16 induced changes at both AcID 
binding surfaces and throughout the Med25 AcID structure, consistent with the tandem 
transcriptional activation domains within its sequence (Figure 2.3) 
Figure 2.3 A: 1H, 15N-HSQC spectra of chemical shifts of Med25 AcID residues. 1H,15N-HSQC spectra of Med25 
AcID show widespread chemical shifts changes upon titration with VP16(438-490). Med25 AcID apo (red), in 
solution with 0.2 (red orange), 0.5 (orange), 0.8 (gold) 1.1 (green), 2 (blue) and 3 (purple) equivalents of VP16. B) 
VP16 binding induces significant (>2 standard deviations above the average chemical shift change) chemical shift 
perturbations in the dynamic regions of  Med25 AcID. This includes residues on the H1 binding surface (blue-green, 
residues I453, Q539 and T54) and the H2 binding surface (red, residues Q456, V471, L464 and R466). HSQC 






ERM binding predominantly lead to perturbations at residues on the H1 surface of the AcID β-
barrel, in agreement with the model in which it preferentially interacts at that site (Figure 
2.4A;).4,6,7 Key changes at residues K411, E538, and Q451, for example, were seen with both 
VP16 and ERM. In contrast, interaction with ATF6α led to significant chemical shifts changes on 
the H2 binding surface (Figure 2.4B). ATF6α induced shifts of residues Q456, M470, and H474 
which were also affected to varying degrees by VP16 and largely unaltered by ERM. This is 
illustrated in Figure 2.4C, which highlights the distinct patterns of overlap of the chemical shift 
patterns of ATF6a and ERM with VP16. Additionally, while the chemical shift perturbations 
indicate that residues in the β-barrel play a role in binding, the extensive shift changes in the 




Figure 2.4: ATF6α binds to the H2 surface of Med25 AcID. (A) Results of chemical shift perturbation experiments 
superimposed upon the Med25 AcID structure (PDB ID code 2XNF). Residues displaying chemical shift 
perturbation greater than 2 SD upon ERM binding are depicted in maize squares. (B) Results displaying chemical 
shift perturbation greater than 2 SD upon ATF6α binding depicted in rust spheres. (C) Scatter plot illustrating 
correlations between the chemical shift perturbations (CSPs) of individual Med25 AcID residues from HSQC 
experiments with ERM, ATF6α, and VP16. The position of each maize square represents the CSP of an individual 
residue in Med25 AcID upon binding to ERM (y axis) and VP16 (x axis). Thus, squares along the dotted diagonal 
are residues that shift similarly in both ERM–AcID and VP16–AcID complexes. The same analysis for ATF6α is 
shown in rust circles. (D) Results of direct binding experiments with fluorescein-labeled activators and the indicated 
mutants of Med25 AcID as measured by fluorescence polarization expressed the fold change relative to the 
dissociation constant of each activator for the WT AcID. The indicated error is propagated from three independent 
dissociation constant measurements. (HSQC experiments completed by Dr. Matthew Henley, Dr. Andrew 
Henderson, and Dr. Brian Linhares; mutant generation and binding studies carried out in collaboration with Dr. Nick 




Consistent with ATF6α and ERM interacting on opposing sides of AcID, mutations introduced on one or 
the other of the binding surfaces produced distinct effects (Figure 2.4D). H1 mutations R538E, K411E, and 
Q451E inhibit ERM binding while ATF6α is largely unaffected. In contrast, H2 mutations R466D and 
M523E significantly inhibit ATF6α with minimal impact on ERM binding. Taken together these data 
indicate that ATF6α binds on the H2 binding surface of Med25 AcID, opposite the site of ERM. Further, 
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the distinct but overlapping chemical shift patterns observed upon binding of each of the activators to 
Med25 suggest several unique binding modes accommodated within AcID. This is analogous to helical 
activator binding domains such as GACKIX of CBP/p300, a three-helix bundle that contains at least two 
activator binding sites.12 
Since a number of charged residues within Med25 exhibited chemical shift changes by ATF6α 
binding, we sought to test if altering the charge could be used to further enhance binding. Within 
the H2 binding surface, M523 was a candidate for mutation as it appears directly adjacent to the 
ATF6α binding site but not directly engaged. Given the overall negative charge of ATF6a, we 
hypothesized that mutation of M523 to glutamic acid would inhibit binding but that mutation to 
arginine would enhance binding. Consistent with this hypothesis, the M523E mutant attenuated 
binding of ATF6α approximately 9-fold. Surprisingly, the M523R mutation did not alter ATF6α 
binding. One explanation is that there is a sufficient array of positively charged residues already 
in the vicinity of the binding surface such that an energetic gain is minimal. The loop flanking the 
binding surface, for example, contains three lysine residues (K518, K519, K520). A more detailed 
mutational analysis will be required to define the roles of the various residues.   
 
2.3A: Minimal 8-Residue Sequences from Activators Are Sufficient for Binding to Med25  
To better understand the important features of activator-coactivator PPIs, it has been a long-
standing strategy to develop synthetic activators, either de novo or by modifying existing activator 
sequences. One of the earliest synthetic designed activators is the 20 amino acid amphipathic helix 
(AH) peptide that has shown that it is possible to create minimal sequences that can function as 
transcriptional activation domains.13–15  Subsequent studies  identified shorter sequences (8-10 
residues) from phage display selections that are capable of low micromolar binding to coactivator 
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protein such as CBP/p300.16  Similarly, truncation studies of natural transcriptional activators 
indicate that sequences of 8-11 amino acids can be sufficient to interact with coactivators and 
stimulate transcription.1718   
Using the reporter gene chloramphenicol acetyl transferase (CAT) driven by a DNA binding 
domain fused to various activator sequences, truncations of activators have identified minimal 
sequences that are capable of interacting with coactivators and the transcriptional machinery for 
transcriptional initiation to occur.  Oaf1 is one of many activators that interact with the TAF9 
coactivator. Using the one-hybrid assay, the transactivation ability of a variety of truncated Oaf1 
TADs was tested in a mammalian cell line and even a 7-residue sequence demonstrated some level 
of activity, with a 10 residue sequence providing robust activation (Table 2.1).17  Truncation 
studies of artificial KIX TADs model from CREB and c-Myb produced 8-residue sequences that 
interact with the cognate coactivator CBP with micromolar affinities.19  Given the structural 
uniqueness of Med25, an open question at the outset of this work was if similar minimal activator 
sequences of transcriptional activators were sufficient to recognize Med25. 
 
Table 2.1: Truncated TAD has transactivation activity in mammalian cells.  Oaf1 TAD minimal sequence was 
identified, and transactivation activity was determined. CAT fold-induction is determined by normalizing CAT to β-
galactosidase activity of cotransfected β-galactosidase plasmid  17 Truncation studies of the Med25 binding 
Construct TAD Sequence Fold Induction 
(CAT) 












partner VP16 carried out in our laboratory revealed that  VP16438-490  interacts with a sub-
micromolar affinity of 60 nM (Figure 2.1).20  Such tight binding arises in part from the ability of 
the nearly full-length transcriptional activation domain to contact both binding surfaces of Med25 
AcID, in contrast to smaller activation domains such as those from ERM and ATF6α. Former 
colleague Dr. Steve Sturlis demonstrated that, consistent with these results, the amino terminus of 
the sequence (residues 413-437) retains little detectable affinity for Med25 AcID (Figure 2.5).  
This set the precedent for further truncation to identify shorter sequences that retained at least 
micromolar affinity for the coactivator and could be used as starting points for peptidomimetic 
design. As illustrated in Figure 2.5, initial studies carried out by Dr. Sturlis revealed that relatively 
short sequences 15-20 amino acids in length retained micromolar affinity for Med25.  
 
Figure 2.5  VP16 TAD Truncation. The VP16 TAD was truncated into three peptides of approximately equally 
length and an additional two peptides were synthesized based on purported α-helices within the TAD (underlined 
sequences within the TAD). The peptides were conjugated to fluorescein and the Kd of each peptide was determined 
for AcID using fluorescence polarization. Curves represent the means of three independent experiments with error 
bars representing the standard deviation of the fraction bound at the indicated concentration of AcID protein  (Data 




Within the C-terminal sequence of 465-490 is a region predicted to become helical upon binding 
to Med25, amino acids 470-485, and an 8-residue sequence (472-479) that has been reported in 
the literature to function as a transcriptional activation domain when fused to a DNA binding 
domain (Table 2.1).15,22 Because VP16(472-479) must interact with coactivators such as Med25 
in order to active transcription, we chose this 8-residue sequence to further investigate. 
VP16(472-479) as well as mutant in which Q477 was replaced with an additional glutamic acid 
were synthesized and labeled with fluorescein for direct binding studies (Figure 2.6). The latter 
was initially prepared as a negative control, as prior studies have shown that increasing negative 
charge in a transcriptional activator sequence typically decreases binding.23,24 
 
Name Sequence 
VP16 (465-490) YGALDMADFEFEQMFTDALGIDEYGG 
VP16 (470-485) MADFEFEQMFTDALGI 
VP16 (472-479) DFEFEQMF 
VP16 (472-479) Q477E DFEFEEMF 
 
Table 2.2 Sequences of the helical region of the C-terminus of the VP16 TAD. The 8-amino acid sequence is 
contained within the longer helical sequences. 
 
As can be seen in Figure 2.6C, VP16(472-479) shows good binding to Med25 AcID, despite its 
considerably smaller size. Additionally, this short peptide preferentially binds to Med25 compared 
to the related activator binding domain of CBP, KIX (Figure 2.6D). However, the negative control, 
the Q477E mutant, showed greater than 2-fold increase in binding (Figure 2.6E). In retrospect, this 
was not an unexpected result; Med25 AcID has an unusually high percentage of positively-charged 
residues relative to other coactivators. Since these experiments were done, Dr. Nick Foster in the 
Mapp lab has carried out studies of Med25 in the presence of salts of different composition and 
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concentrations and found that indeed, activator binding to Med25 is substantively dependent upon 




Figure 2.6: Direct binding assays of VP16 ligands to coactivator proteins. A. WT 8- amino acid sequence (VP16 472-
479 bind to Med25 AcID with low micromolar affinity. B. Replacing the glutamine with glutamic acid retains low 
micromolar affinity for Med25 AcID. C. The WT ligand was tested for binding to CBP KIX and the KD could not be 
determined under the conditions used. The curves were obtained from plotting three the mean of three independently 
run experiments. The errors represent the standard deviations (Some error bars are smaller than data point symbols). 
 
Further examination of the sequence of VP16 revealed a second 8 residue sequence (441-448) with a very 
similar sequence to VP16(472-479), termed VN8 in the literature.22 Additionally, a nearly identical 
sequence is observed in the activator ATF6α, residues 61-68. We hypothesized that the ATF6α VN8 
sequence would function similar to the VP16 sequence and interact with Med25 AcID. To test this, the 
sequence was synthesized by standard methods and direct binding experiments revealed an affinity of 6.1 
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± 0.5 µM for Med25 AcID (Figure 2.7). This peptide also showed good selectivity for Med25, with little 
binding to a coactivator with a similar set of binding partners, the KIX motif of CBP/p300. Thus, this 
octameric peptide similar seemed like a good starting point for peptidomimetic design. 
 
 
ATF6α VN8 = DFDLDLMP 
 
 
Figure 2.7: ATF6α VN8 Peptide shows selectivity for Med25 AcID. The curves were obtained from plotting the 




Kd > 25 µM 




2.4 Conclusions   
Med25 AcID is a transcriptional coactivator with a unique structure that nonetheless interacts with 
its transcriptional activator binding partners through a mechanism similar to that of other 
coactivators. Prior work and the results in this chapter illustrate that Med25 AcID uses two distinct 
binding surfaces located on opposite sides of its central β-barrel to interact specifically with 
different TAD sequences. More specifically, structural and biophysical experiments illustrated that 
the activators ERM and ATF6α interact with opposing binding surfaces on the β-barrel, the H1 
and H2 sites, respectively. Med25 is a potential therapeutic target for breast and prostate cancer 
and as such, it would be especially useful to be able to target those two sites with synthetic ligands. 
Building on previous work done in the Mapp lab, we sought to identify minimal peptide sequences 
capable of interacting with Med25 that could then be used to design peptidomimetic inhibitors. By 
truncating the VP16 TAD we identified two different octamer sequences that retain single digit 
micromolar KDs. And, preliminary data suggests that these sequences have at least modest 
selectivity for Med25 relative to other coactivators. A similar octamer sequence was found in 
another Med25 binding partner, ATF6α. Taken together these studies suggest that short peptides 
are an excellent starting point for the development of Med25 inhibitors, a strategy that is 







2.5 Materials and Methods 
The pET21b-Med25 (394-543)-His6 plasmid was a generous gift from the Patrick Cramer lab. The 
mutations were carried out through standard site-directed mutagenesis protocols. 
Protein Expression and purifications  
Med25 AcID(394-543) was purified by following standard expression protocols. The pET21b-
Med25 (394-543)-His6 plasmid was transformed into heat-shock competent Rosetta pLys cells 
(Novagen) and plated onto LB plates containing ampicillin and chloramphenicol antibiotics then 
placed in the incubator inverted at 37 °C overnight for approximately 15-16 hours. The plates were 
then placed at 4 °C until needed. Starter cultures were prepared by pipetting 5 ml of Luria Broth 
into two disposable culture tubes each followed by 0.1 mg/ml ampicillin and 0.034mg/mL 
chloramphenicol. Using a sterile pipette tip, a single isolated colony was selected from the 
transformed plate and placed in each of the culture tubes after which the tubes were placed in an 
incubator at 37 °C with a rotation speed of 250RPM overnight. The following morning 1-2 mL of 
the starter culture was placed in 1L autoclaved Terrific Broth along with 0.1mg/mL of ampicillin, 
then placed in an incubator at 37 °C at 250 RPM and grown to an OD600 of 0.8-1.0. The culture 
was placed in an incubator at 18 °C for at least 30 minutes before the cells were induced with 0.2 
mM Isopropylβ-d-1-thiogalactopyranoside (IPTG) and shaken at 200 RPM overnight. The following 
morning the cells were collected and centrifuged at 6000 x g RPM for 20 minutes at 4 °C. The 
pellets were collected and placed in 50 mL centrifuge tubes, centrifuged at 2000 RPM for 2 
minutes to concentrate the pellet to the tube bottom then stored at -80 °C for later purification. 
Med25 AcID was purified using manual protocol involving Ni-NTA resins and an automated 
protocol Ni-NTA 5mL HiTrap FPLC columns. The collected pellet was suspended in 35 mL lysis 
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buffer (50 mM phosphate, 300 mM sodium chloride, 10 mM imidazole, pH 7.2) with 35 µL β-
mercaptoethanol (1:1000 dilution)and  one cOmplete, Mini, EDTA-free Protease Inhibitor tablet 
(Sigma-Aldrich). The cells were then lysed via sonication on ice for a total of 6 minutes with pulse 
on for 3 seconds and off for 10 seconds. After the cells were fully lysed, the solution was placed 
in a 50 mL centrifuge tube and placed in a fixed angle centrifuge rotor to centrifuge at 9500 RPM 
for 30 minutes at 4 °C. At the completion of the spin cycle, the supernatant was poured into a new 
50 mL centrifuge tube then placed back in the centrifuge and spun at 9500 RPM for 10 minutes at 
4 °C to further separate large particulates. The supernatant from the second centrifugation was 
filtered into a clean 50 mL centrifuge tube using 0.45 µm syringe filters and placed on ice. 
The supernatant was loaded onto a 5 mL Ni-NTA HiTrap  equilibrated with Buffer A/Lysis Buffer 
( 50 mM phosphate, 300 mM sodium chloride, 10 mM imidazole, pH 7.2) on an AKTA pure FPLC 
chromatography system. The sample was loaded onto the column at a rate of 2.5 mL per minute. 
The method was created to follow the following sequence: the loaded column was washed with 5 
column volumes of Buffer A, then with 5 column volumes of 10% Buffer B (50 mM phosphate, 
300 mM sodium chloride, 400 mM imidazole, pH 7.2), followed by a wash with 5 column volumes 
of 15% Buffer B: 85% Buffer A and finally, elution with a gradient from 15-100% Buffer B. The 
column was subsequently washed with 5 column volumes of 100% Buffer B.  
Following the collection of the fractions, those containing the Med25 AcID protein were collected 
and combined into a chilled 50 mL centrifuge tube then diluted to 50 mL using chilled (4 °C) 
Source S buffer A (50 mM phosphate, pH 7.2). 
The Med25 AcID protein was further purified using 5 mL Source S HiTrap column using the 
AKTA pure FPLC chromatography system. The column was equilibrated with Source S buffer A 
(50mM phosphate, pH 7.2) then the diluted sample was loaded onto the column. Next, the column 
43 
 
was washed with 5 column volumes of Buffer A. Next, the protein was eluted with high 
concentration of sodium ions as the column was washed with 10 column volumes over a 
concentration gradient of 0-100% Buffer B (50 mM phosphate, 1M sodium chloride, pH 7.2). The 
fractions were collected and analyzed via SDS-PAGE using a 12% acrylamide gel. The pure 
fractions were then combined and 1 mM DTT was added then buffer exchanged in storage buffer 
(10mM phosphate, 100mM sodium chloride, 10% glycerol, 1 mM DTT, pH 6.8) overnight. The 
protein was concentrated and stored in 150 µL aliquots at 100-200 µM concentrations at -80 °C. 
Protein concentrations were determined using UV-Vis spectroscopy with the extinction 
coefficient, ε = 22550 M-1cm-1 and mass confirmation was carried out by electrospray mass 
spectrometry. 
Site-Directed Mutagenesis  
Primers used for site-directed mutagenesis  








































Peptide Synthesis  
Peptide synthesis was carried out using conventional solid phase peptide synthesis and microwave 
assisted peptide synthesis (CEM Liberty Blue).  
Peptides were synthesized on 50 µmole scale using CEM rink-amide resin (0.19-0.21 meq). The 
synthesis was carried out with dimethylformamide as the main solvent. Fmoc-amino acid 
concentrations were made to be 0.2M, deprotection solution was made up containing 20% 
piperidine, 0.2M Oxyma Pure. Diisopropylcarbodiimide (DIC) was the activator acid and Oxyma 
Pure was the activator base. The amino acids were coupled using 4-minute single coupling for 
peptide sequences shorter than 20 amino acids. The peptides were cleaved with 95% TFA:2.5% 
TIPS: 2.5% H2O. Excess cleavage cocktail was evaporated using nitrogen gas flow. The resulting 
solution was treated with cold diethyl ether then centrifuged to collect the peptide precipitate. The 
ether was decanted, and the pellet was redissolved in 30% 0.1% TFA/H2O and acetonitrile and 
lyophilized before purification. Peptides were redissolved in minimal acetonitrile (25%) and 0.1% 
TFA/H2O solution and purified using reverse-phase HPLC (Agilent) with C-18 columns and 
0.1%TFA/H2O-acetonitrile solvent system. The purified fractions were collected and analyzed 
using mass spectrometry. These pure fractions were combined after identifying through mass 




Manual Peptide Synthesis 
Peptides were synthesized using CLEAR amide resin (Peptide International) or rink amide resin 
(CEM). Manual synthesis reagents for CLEAR rink amide resin were HOBT, HBTU and DIPEA 
and that for CEM rink amide was DIC and HOBT. The first amino acids were coupled for a 
minimum of six hours followed by 2 hours of amino acid coupling up to the 10th residue and 
subsequently 2.5 hours beyond 10 residues. After the completion of the sequence, the N-terminus 
was deprotected. For fluorescein labeling, beta alanine was coupled to the N-terminus and then 2 
eq fluorescein isothiocyanate was coupled in the presence of 4 eq DIPEA. The N-terminus was 
acetylated for unlabeled peptide using 50 eq acetic anhydride and 50 eq DIPEA. 
The peptides were cleaved with 95% TFA:2.5% TIPS: 2.5% H2O. Excess cleavage cocktail was 
evaporated using nitrogen gas flow. The resulting solution was treated with cold diethyl ether then 
centrifuged to collect the peptide precipitate. The ether was decanted, and the pellet was 
redissolved in 30% 0.1% TFA/H2O and acetonitrile and lyophilized before purification. Peptides 
were redissolved in minimal acetonitrile (25%) and 0.1% TFA/H2O solution and purified using 
reverse-phase HPLC (Agilent) with C-18 columns and 0.1%TFA/H2O-acetonitrile solvent system. 
The purified fractions were collected and analyzed using mass spectrometry. These pure fractions 
were combined after identifying through mass spectrometry and lyophilized until a dry powder 
was left.  
The peptide was dissolved in DMSO. A sample of the DMSO was diluted 1:1000 in storage buffer 
to ascertain the concentration. Using UV-Vis, the concentration was measured at λ=495 nm for 





Fluorescence Polarization  
Fluorescence polarization direct binding assays were done in triplicate with a final volume of 20 
µL in a low volume, non-binding, 384-well black plate (Corning). Fluorescein-labeled DMSO 
peptide stocks were diluted to 50 nM using assay buffer (5 mM HNa2PO4, 5 mM NaH2PO4, 100 
mM sodium chloride, 10 % glycerol, pH 6.8). 10 µL of Med25 AcID was serially diluted two-fold 
going down the column of the 384-well plate using the assay buffer (10 µL assay buffer was placed 
in each well). No protein was added to the last row as it was a negative control with peptide only. 
Finally, 10 µL of peptide was added to each well to provide a final peptide concentration of 25 nM 
and the resulting mixtures left to incubate at room temperature for 30 minutes. After 30 minutes, 
the fluorescence polarization was measured using Tecan Genios Pro or PHERAstar plate reader 
(polarized excitation at 485 nm and emission intensity measured through a parallel and perpendicularly 
polarized 535 nm filter). Data was analyzed by binding isotherm that accounts for liganddepletion 
(assuming a 1:1 binding model of peptide to ACID) was fit to the observed 
polarization values as a function of AcID to obtain the equilibrium dissociation, 
Kd. Each data point is an average of the triplicate experiments from each peptide with Med25 AcID 
and the error for standard deviation. “a” and “x” are the total concentrations of fluorescent peptide and 
Acid, respectively, “y” is the observed anisotropy at a given AcID concentration, “b” is the maximum 
observed anisotropy value, and “c” is the minimum observed anisotropy value.  
𝑦 = 𝑐 + (𝑏 − 𝑐) 𝑋 
(𝐾𝐷 + 𝑎 + 𝑥) − [√(𝐾𝐷 + 𝑎 + 𝑥)
2 − 4𝑎𝑥]
2𝑎
    
 
Fold change =  
 𝐾𝐷 for Mutant Med25 AcID−peptide interaction





Fold Change = 
 𝐾𝐷 for  Med25 AcID−minimal peptide interaction
KD for Med25 AcID−full−length peptide interaction
 
  
1H, 15N-HSQC NMR analysis of Med25 AcID-peptide 
Purified 15N- labeled Med25 AcID protein was complexed with purified N-acetylated peptides at 
varying equivalents. The experiments were carried out using a Bruker Advanced III 600 MHz 
spectrophotometer equipped with a cryogeneic probe at 30 °C. The varying titrations were done 
using Med25 AcID stored in 15N-Med25 storage buffer (20 mM sodium phosphate, 150 mM 
sodium chloride, 5% D2O, pH 6.5) with a final concentration of 73 µM. Acetylated peptides were 
added at 0, 0.2, 0.5, 0.8, 1.1, 2 and 3 equivalents and 2% final DMSO concentration. Our control 
sample was with Med25 and DMSO only. Two stocks of each peptides were prepared at 
concentrations of 2.5 and 25 mM. To keep the DMSO concentration at 2%, the 2.5 mM stock was 
used for 0.2, 0.5 and 0.8 equivalents samples and the 25 mM stock was used for the 1.1, 2 and 3 
equivalents. Data processing and visualization was performed using NMR pipe and Sparky. 
 
Circular Dichroism 
Circular Dichroism (CD) spectra of Med25 was obtained using J-715 spectropolarimeter (Jasco 
Inc) using a 1mm path length quartz cuvette. The Med25 protien was dialyzed overnight into CD 
buffer (5mM NaH2PO4, 5mM Na2HPO4, 100 mM NaF, pH 6.8). The spectra was measured from 
260-180 nm at 1 nm increments at 200 nm/minute. A baseline spectra was obtained using CD 
buffer only followed by measurement of Med25 AcID at 25 µM. The background spectra was 
subtracted from that of the protein before converting to mean residue ellipticity, θ using the 
following equation, where ψ = is the cd signal in degrees, n is the number of residues, l is the path 





1000 ∗ 𝑛 ∗ 𝑙 ∗ 𝑐
 
 
Circular Dichroism-Observed Thermal Melt 
After the CD spectra were collected, a CD-observed thermal melt spectrum was collected using 
without changing the buffer mentioned above. This was done using the variable temperature 
module. The protein was heated from 20- 100 °C by increasing the temperature at 1°C per minute. 
The spectrum was monitored at 222 and 208 nm. The data was collected using every two degrees 
throughout the interval. The data was then converted to Fraction unfolded and Tm was determined 
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Peptoid Transcription Factor Mimics Interact with Med25 and Are Cell Penetrant 
3.1 Abstract 
Targeting activator-coactivator interfaces has been a challenge in part due to the structurally 
dynamic nature of the complexes. Additionally, the binding interface is typically large and thus 
small molecules ligands have shown little success. Alternatively, peptoids have been used as an 
effective synthetic tool to mimic and modulate protein-protein interactions. Most notable is their 
ability to mimic peptides and capability of covering larger surface areas. In this Chapter, we 
demonstrate that peptoids based upon the minimal activator sequences identified in Chapter 2 
have similar affinity for Med25 as do the native binding partners. The affinity can be enhanced 
by incorporating additional activator sequences. We tested the hypothesis that a helical peptoid 
would exhibit further affinity enhancement and, unexpectedly, found that this did not increase 
the potency. Additionally, we were also able to modify the peptoids to improve the efficiency of 
transportation across the plasma membrane. Thus, the peptoids Med25 ligands developed here 
will be useful tools for mechanistic studies of the Med25 PPI network. 
 
3.2 Introduction 
It has been established that transcription regulation is essential for the successful conversion of 
genetic information to proteins, and that dysregulation of this process can result in disease.1–5 
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Although the protein-protein interactions (PPIs) involved in the assembly of the transcriptional 
machine are thus attractive therapeutic targets, the characteristics of these proteins render them 
difficult to target with ligands; these characteristics include the large surface areas of the proteins, 
the transient nature of these interactions, the weak to moderate affinities for binding to partners, 
and the lack of high resolution structural information due to the disordered nature of the binding 
partners. All these characteristics have led to many activator-coactivator interactions being labeled 
as “undruggable.” Consistent with the above characterization, multiple strategies have been 
employed in targeting activator-coactivator interactions with small-molecules and yet have not 
yielded much success. Coactivator complex formation requires more points of contact than can 
easily be recapitulated with small molecules.  
An excellent example of an important yet challenging coactivator is the focus of this work, Med25 
(Figure 1.1). Within Med25 is the Activator-Interaction Domain (AcID) that forms protein-protein 
interactions with several activators, including VP16, the ETV/PEA3 activators, and ATF6. The 
AcID PPI network is dysregulated in a number of cancers either through upregulation of Med25 
or through upregulation of the binding partners. For example, the Merajver lab at the University 
of Michigan has found several examples of triple-negative breast cancers with significant 
upregulation of Med25 and in our group’s collaborative work with them, genetic or 
pharmacological inhibition of Med25 decreases cell motility as well as markers of metastasis.6–8 
There has thus been great interest in identifying small molecule ligands of Med25 but the 900 Å2 
binding surfaces have been a nearly insurmountable barrier.  
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Figure 3.1 The coactivator Med25 has three domains: a VWA domain that interacts with the Mediator complex, the 
Activator Interaction Domain (AcID) that forms PPIs with transcriptional activators and coactivators, and the 
Nuclear Receptor (NR) motif that is an interaction site for several nuclear receptors. Figure adapted from 
doi: https://doi.org/10.1101/2021.03.26.437253 and created by Amanda Peiffer. 
 
An alternative to small molecules is the use of peptidomimetics. In particular, N-substituted 
glycine oligomers or peptoids have been proven to be potent ligands of a number of different 
challenging PPI interfaces.9–11 Peptoids are suitable for interacting with larger surface areas 
because structures as long as 48 monomers can be synthesized in a machine-assisted fashion, with 
each monomer containing a functional group that can potentially interact with the target. Another 
key property of peptoids is the ease with which diverse side chains can be introduced into the 
structures. Thus, functional groups that are identified in fragment screenings or other target studies 
can be readily incorporated into the larger structure of a peptoid.12–14 Further, incorporation of 
chiral side chains into the oligomer induces helicity to the structure, thus enhancing affinity in 
cases where the preferred binding conformation is a helix.15 Finally, this class of peptidomimetic 
is resistant to proteolytic degradation due its non-native amide backbone.16 
Consistent with the above description, there are examples of successful targeting of coactivators 
and other transcriptional proteins with peptoids. For example, our group has successfully identified 
peptoids based upon the sequence of synthetic peptides discovered by Montminy that 
demonstrated improved binding to the GACKIX domain of CBP by ~6-fold (Figure 3.2).17–19 This 
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suggests that the conformational flexibility of peptoids could be advantageous for interacting with 
dynamic protein surfaces.   
 
Figure 3.2 Peptoid improve binding to KIX. Previous work from the Mapp lab showed that peptoid variants of 
peptide ligands for the KIX motif of CBP/p300 showed improved binding. a) Illustration of KIX bound to a native 
partner, CREB. b) Sequences of natural transcriptional activators (CREB, cMyb) and non-natural ligands (KBP 
1.66, 2.20) that bind to KIX. c,d) Schematic of peptidomimetic variants of the KBP 1.66 and KBP 2.20. Figure 
adapted from Biopolymers, Volume: 89, Issue: 7, Pages: 578-581, DOI: (10.1002/bip.20946)  
 
In Chapter 2 I demonstrated that peptides as short as 8 residues derived from native transcriptional 
activators were sufficient to complex to Med25. In this Chapter, I test the hypothesis that peptoid 
variants of these sequences will interact with Med25 AcID and in doing so serve as ligands for 
future mechanistic studies. I identify an effective and stable Med25 ligand that will be an important 







3.3 Results and Discussion 
As shown in the data of Chapter 2, I identified two octamer peptides derived from the Med25-
dependent activators VP16 and ATF6a that retain low micromolar affinity for Med25 (Table 1). 
These octamers thus served as the starting point for peptoid ligand design.  
Peptide name Sequence  KD for Med25 
VP16(472-479) DFEFEQMF 8 ± 1 M 
ATF6 VN8 DFDLDLMP 6.1 ± 0.5 M 
  
Table 3.1: Octamer peptides interact with Med25 AcID with low micromolar affinity 
 
The sequence of VP16(472-479) can be mapped onto a peptoid backbone in a straightforward 
fashion (Figure 3.2), as it simply requires moving the amino acid side chain in the peptide to the 
adjacent amine. This produces an achiral amide polymer that can be readily synthesized by solid 
phase synthesis. Each monomer is constructed on the resin, via coupling of bromoacetic acid to 
the growing peptoid chain followed by addition of a primary amine bearing the relevant side chain 
that is suitably protected. There are constraints presented by this synthetic strategy, however, as 
some functional groups are incompatible with the synthetic procedure, either due to reactivity 
issues (methionine, asparagine/glutamine) or due to solubility challenges.20 To address this in my 
peptoid design methionine was replaced with a simple hydrophobic side chain and the glutamine 
residue was replaced with glutamic acid. In the latter case, this particular change was found to 
enhance binding affinity of the peptide (Chapter 2, Figure 2.6). Peptoid 1 was synthesized on an 
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automated peptide synthesizer and was purified by HPLC. The identity and purity were verified 
by mass spectrometry and by analytical HPLC analysis. 
 
Figure 3.3: VP16(472-479) minimal peptide sequence. The peptoids were designed by substituting amines that 
mimic the side chains of the corresponding amino acids. Methionine replaced by norleucine mimic (norleucine 
commonly replaces methionine to avoid oxidation).  
 
Following synthesis and isolation of peptoid 1, the structure of the peptoid in solution was assessed 
using circular dichroism at 25 °C. The molar residual ellipticity was measured from 260-185 nm 
with 5 scans that were averaged and mean residual ellipticity was calculated from the measured 
ellipticity observed in millidegrees. As expected with an achiral peptoid, a net mean residual 
ellipticity of zero was observed.  
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The affinity of peptoid 1 for Med25 AcID was measured using fluorescence polarization. To 
accomplish this, peptoid 1 was labeled at the amino terminus with fluorescein isothiocyanate for 
use in binding assays. Following standard protocols, the KD was determined to be 6.7 ± 0.2 µM 
(Figure 3.3). This demonstrates peptoid peptidomimetics can successfully recapitulate binding of 
even a minimal transcriptional activator, despite lacking the backbone hydrogen bonding network 
that even in short peptides facilitates secondary structure formation upon binding. The data further 
suggest that this is a lead compound that can be modified improve affinity for Med25 and 
ultimately inhibitor potency. 
 




















Figure 3.4 Results from a fluorescence polarization assay of peptoid 1 in the presence of increasing concentrations of 
Med25 AcID. The curve represents the mean of three independent experiments ran in triplicate with the error 
representing the standard deviation. 
 
3.3A Inducing Secondary Structure by Introducing Chirality 
Next, I tested the hypothesis that a helical peptoid would have improved affinity for Med25. We 
sought to induce helical structure of the peptoid by incorporating structural elements that have 
K
d
= 6.7 ± 0.2 µM 
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induced helical conformation in peptoids.21,22 It has been established that TADs remain largely 
unstructured in free solution; however, upon binding to their coactivators they adopt an α-helical 
conformation.15,23 By extension, amines with aromatic α-chiral side chains have been 
demonstrated to successfully induce helical conformations in peptoids by forming polyproline-like 
helices. As a result of this, we substituted the aromatic achiral side chain, benzylamine, with (S)-
(-)-α-methylbenzylamine to mimic an L-amino acid. To mimic a peptide constructed of D-amino 
acids, we introduced (R)-(+)-α-methylbenzylamine (Figure 3.4). The secondary structure of both 
peptoids was measured using circular dichroism and the mean residual ellipticity confirms a 
secondary structure profile that matches that of the enantiomer of the L-peptidomimetic, which 




Figure 3.5: Structures of chiral versions of peptoid 1. (S)- (-)-α-methylbenzylamine (Nspe) and (R)- (+)-α-





Figure 3.6: CD spectra of peptoids. Induced secondary peptoid structure for peptoids 2a (orange) and 2b (blue). Mean 
residue ellipticity measured using circular dichroism of peptoids with (R)- or (S)- monomers.  
 
The affinities of the chiral peptoids were measured using fluorescence polarization assays. The 
conditions mentioned above were used to set up the experiments using these modified compounds. 
Peptoids 2a and 2b were shown to be 10 ± 1 µM for both, indicating that the stereochemistry of 
peptoids does not strongly affect the interaction with Med25. It is not surprising that the 
enantiomers show similar binding, as this has been shown with transcriptional activator peptides 
in several cases. It is, however, the first demonstration with a peptoid. It was somewhat unexpected 
that the helical peptoids bound essentially identically to the parent, unstructured peptoid, since the 




























Figure 3.7: Fluorescence polarization assay. Enantiomeric peptoids containing chiral aromatic monomers show 
identical affinity for Med25 AcID. 
 
From the information garnered from the VP16(472-479)-derived peptoids, I concluded that 
octamer peptoids are sufficient for moderate binding to Med25 and began to investigate if other 
octamer sequences such as ATF6 VN8 (Table 1), would show similar or even better affinity.  I 
designed a peptoid based upon the ATF6 VN8 peptide, illustrated in Figure 3.8.   
Kd = 10 ± 1 µM 






Figure 3.8 Structures of ATF6α (61-68), also known as VN8 as well as two peptoids derived from that sequence. 
Note that peptoid 4 is a peptide-peptoid hybrid.  
 
The peptide ATF6 VN8 was synthesized and tested against Med25 AcID for affinity and, as 
originally shown in Chapter 2, the resulting dissociation constant is 6 µM (Figure 3.9). Following 
this, the peptoid 3 was synthesized using (S)-(-)-α-methylbenzylamine as the mimic for the 
monomer phenylalanine. Upon completion and assessment of the net mean residual ellipticity, the 
peptoid were labeled at the amino terminus with fluorescein and the affinity for Med25 AcID was 
measured using fluorescent polarization. As shown in Figure 3.9, peptoid 3 had significantly 
attenuated affinity relative to the parent peptide (>10-fold decrease). However, the peptoid did 
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retain selectivity for Med25 AcID, (2-fold). For this reason, the focus on ATF6-derived peptoids 
continued, with the goal of increasing the affinity while retaining or improving the selectivity. 
 
Figure 3.9: VN8-Med25 AcID direct binding. Results of direct binding experiments with fluorescein-tagged variants 
of ATF6α VN8, peptoid 3, and ATF6α (40-60). Three independent experiments were done in triplicate with 
curves representing the mean. The errors represent the standard deviation.  
 
3.3B Increasing the Peptoid length Improves the Binding Affinity for Med25 AcID 
As shown above, octamer peptoids can display good (<10 µM) affinity for Med25. However, 
peptoid 3 displayed modest affinity for the target and it was necessary to improve this, particularly 
for cellular studies. One established strategy for increasing affinity of peptoids is the appendage 
of short peptide sequences to the peptoid core. In our case, ATF6α (40-60) was added to peptoid 
3 to create peptoid 4 (Figure 3.8). The resulting peptoid-peptide hybrid showed a much-improved 
binding to Med25 AcID (Kd of 3 µM). This is not solely due to the intrinsic affinity of the peptide 




= 6.1 ± 0.5 µM 
K
d 
> 58 ± 12 µM 
K
d
= 2.5 ± 0.4 µM 
ATF6 VN8 
Peptoid 3 
Peptoid 4  
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Given the results of the peptide-peptoid hybrid 4, I synthesized and tested a wide range of peptoids 
and peptoid-peptide hybrids that incorporated additional components of the ATF6α transcriptional 
activation domain (Figure 3.10).  
 
 
Figure 3.10. Peptoids and peptide-peptoid hybrids. ATF6α-derived peptoids and peptide-peptoid hybrids designed 




All of the peptide-peptoid hybrids and peptoids were labelled with fluorescein and assessed in 
direct binding assays with Med25 AcID. Hybrids 5 and 6 differed in affinity two-fold. A third 
hybrid tested was the ATF6α(40-60) sequence in which the alanine residues at positions 48 and 48 
were replaced with N-methyl glycine (labeled ATF6α(40-60)* in the figure). However, the affinity 
was unchanged from the peptide alone.  
Most interesting were the results from peptoids 7 and 8, which show improved binding compared 
to peptoids 5, 6 and ATF6α 40-60* (alanine replaced with N-methyl glycine) despite being shorter 
sequences. The peptoid based upon ATF6α (60-70) (peptoid 7) is shorter than the hybrid and 
peptide sequences but showed a significantly improved affinity of 7.7 M.  Replacement of the 
proline with a chiral phenylalanine mimic in peptoid 8 further increased the affinity to 3.6 M.  
 
Figure 3.11: Results of direct binding experiments with fluorescein-tagged variants of ATF6α with Med25 AcID. 
Three independent experiments were done in triplicate with curves representing the mean. The errors represent 
the standard deviation.  
5: 19 ± 3 µM 
ATF6 (40-60): 12 ± 1.0 µM 
ATF6 (40-60)*:  12.4 ± 0.7 µM 
6: 9.0 ± 0.4 µM 
7: 7.7 ± 0.3 µM 






As noted earlier, one of the key questions was if the peptoid ligands could maintain selectivity for 
Med25 AcID over other coactivators. To test this, the affinity of each were measured for a 
coactivator with a similar binding profile, the KIX domain of CBP/p300 (Figure 3.12). These 
experiments revealed that lead peptoid 8 shows nearly five-fold selectivity for Med25 AcID, an 




Figure 3.12 Results of direct binding experiments with fluorescein-tagged variants of ATF6α with CBP KIX. Three 




5: > 40 µM 
ATF6 (40-60): > 71 µM 
ATF6 (40-60) *:  > 102 µM 
6: > 47 µM 
7: > 21 µM 











From the direct binding studies above, peptoid 8 was shown to have a good affinity for Med25 
AcID and good selectivity relative to CBP KIX. With this promising result, we sought to modify 
the structure so that it would be transported across the plasma membrane for delivery. Earlier 
studies have identified the HIV-TAT sequence as an effective cell penetrating peptide (CPP) and 
has been used to delivery cargo to cells.24–28 CPPs are generally short to moderately long sequences 
with positively charged amino acid repeats. This aids in their ability to travel across the plasma 
membrane with little to no resistance. HIV-1 TAT49-57 has shown to aid in cell penetration by 
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keeping the structure to a minimum of 9 residues.29 Appending the TAT to a net negatively charged 
sequence converts the structure to a net positively charged molecule, increasing the probability of 
transportation across the negatively charged membrane. For the TAT-containing peptoid 10, 
fluorescein was added to the N-terminus of the TAT sequence to allow for visualization of the 
molecule in cell-penetration studies.  In parallel a second strategy was explored with peptoid 9, 
one in which the carboxylic acid side chains were masked as methyl esters expected to be 
hydrolyzed intracellularly.30 To complete the design of the molecule I selected TAMRA as the 
fluorophore due to its neutrally charged state.  
In collaboration with colleague Yejun Liu, the permeability of peptoids 9 and 10 were assessed in 
the triple negative breast cancer cell line VARIO68.8,31  Cells were treated with 9 or 10  with a 
final concentration of 115 µM then observed under a confocal microscope  at 3- and 6-hour 
intervals. After three hours (top panel) peptoid 9 shows increased trafficking relative to 10. This is 
also true at the 6-hour time point (bottom pane), with peptoid 9 appearing to show nuclear entry.  
In contrast, 10 appears to be largely trapped in endosomes (green punctae), a common issue.32,33 
Taken together, these modifications and derivatives of the compounds have suggested that the ester 
modification as the bioactive precursor would be more effective due to the passive diffusion across 
the cell membrane.30 These initial studies have provided valuable information to guide design of 




Figure 3.14 Peptoid permeability. Peptoid 8 was modified by appending the CPP TAT (left pane), modified acidic 
residues for ester (right pane). They were labeled with the fluorophore FITC or TAMRA. DAPI used to visualize 
nucleus. Some fluorophores enhance endosomal entrapment. Here, TAT seems to promote endosomal entrapment.  
 
3.4 Conclusions and future Directions 
Peptoids have long been used as one class of peptidomimetics for developing ligands for different 
classes of PPIs.   In this Chapter I hypothesized that I could leverage the characteristics of peptoids 
to develop minimal sequence molecules that can bind to coactivators with low micromolar affinity. 
I showed that I could develop two peptoids with low micromolar affinities for the coactivator while 
maintaining specificity. This created the opportunity to further optimize the ATF6α peptoid since 
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it had an 8-fold weaker compared to the VP16. Amino acids flanking the core sequence allowed 
us to increase the length of the peptoid and improve binding. The resulting 11-residue sequence 
showed lower micromolar affinity and specificity for Med25 AcID. I demonstrated that we could 
deliver this sequence into cells by creating an ester derivative (peptoid 9).  
The results from these studies present questions to be answered in future studies. One such question 
to be addressed is how peptoid 9 affects the Med25 PPI network in vitro and in cell culture. My 
preliminary data suggests that the peptoid ligands enhance the binding of VP16-derived activators; 
the next question will be to test the full complement of Med25-dependent activators in such studies 
(ATF6α, the ETV/PEA3 activators). Additionally, a structural model of how peptoid 8 interacts 
with Med25 would be very useful for further optimizing the structure.  Towards that end, 1H, 15N 












3.5 Materials and Methods 
The pET21b-Med25 (394-543)-His6 plasmid was a generous gift from the Patrick Cramer lab. The 
mutations were carried out through standard site-directed mutagenesis protocols. 
Protein Expression and Purifications  
Med25 AcID(394-543) was purified by following standard expression protocols. The pET21b-
Med25 (394-543)-His6 plasmid was transformed into heat-shock competent Rosetta pLys cells 
(Novagen) and plated onto LB plates containing ampicillin and chloramphenicol antibiotics then 
placed in the incubator inverted at 37 °C overnight for approximately 15-16 hours. The plates were 
then placed at 4 °C until needed. Starter cultures were prepared by pipetting 5 ml of Luria Broth 
into two disposable culture tubes each followed by 0.1 mg/ml ampicillin and 0.034mg/mL 
chloramphenicol. Using a sterile pipette tip, a single isolated colony was selected from the 
transformed plate and placed in each of the culture tubes after which the tubes were placed in an 
incubator at 37 °C with a rotation speed of 250 RPM overnight. The following morning 1-2 mL of 
the starter culture was placed in 1L autoclaved Terrific Broth along with 0.1mg/mL of ampicillin, 
then placed in an incubator at 37 °C at 250 RPM and grown to an OD600 of 0.8-1.0. The culture 
was placed in an incubator at 18 °C for at least 30 minutes before the cells were induced with 0.2 
mM Isopropylβ-d-1-thiogalactopyranoside (IPTG) and shaken at 200 RPM overnight. The following 
morning the cells were collected and centrifuged at 6000 x g RPM for 20 minutes at 4 °C. The 
pellets were collected and placed in 50 mL centrifuge tubes, centrifuged at 2000 RPM for 2 
minutes to concentrate the pellet to the tube bottom, then stored at -80 °C for later purification. 
Med25 AcID was purified using manual protocol involving Ni-NTA resins and an automated 
protocol with Ni-NTA 5mL HiTrap FPLC columns. The collected pellet was suspended in 35 mL 
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lysis buffer (50 mM phosphate, 300 mM sodium chloride, 10 mM imidazole, pH 7.2) with 35 µL 
β-mercaptoethanol (1:1000 dilution)and  one cOmplete, Mini, EDTA-free Protease Inhibitor tablet 
(Sigma-Aldrich). The cells were then lysed via sonication on ice for a total of 6 minutes with pulse 
on for 3 seconds and off for 10 seconds. After the cells were fully lysed, the solution was placed 
in a 50 mL centrifuge tube and placed in a fixed angle centrifuge rotor to centrifuge at 9500 RPM 
for 30 minutes at 4 °C. At the completion of the spin cycle, the supernatant was poured into a new 
50 mL centrifuge tube then placed back in the centrifuge and spun at 9500 RPM for 10 minutes at 
4 °C to further separate large particulates. The supernatant from the second centrifugation was 
filtered into a clean 50 mL centrifuge tube using 0.45 µm syringe filters and placed on ice. 
The supernatant was loaded onto a 5 mL Ni-NTA HiTrap  equilibrated with Buffer A/Lysis Buffer 
( 50 mM phosphate, 300 mM sodium chloride, 10 mM imidazole, pH 7.2) on an AKTA pure FPLC 
chromatography system. The sample was loaded onto the column at a rate of 2.5 mL per minute. 
The method was created to follow the following sequence: the loaded column was washed with 5 
column volumes of Buffer A, then with 5 column volumes of 10% Buffer B (50 mM phosphate, 
300 mM sodium chloride, 400 mM imidazole, pH 7.2), followed by a wash with 5 column volumes 
of 15% Buffer B: 85% Buffer A and finally, elution with a gradient from 15-100% Buffer B. The 
column was subsequently washed with 5 column volumes of 100% Buffer B.  
Following the collection of the fractions, those containing the Med25 AcID protein were collected 
and combined into a chilled 50 mL centrifuge tube then diluted to 50 mL using chilled (4 °C) 
Source S buffer A (50 mM phosphate, pH 7.2). 
The Med25 AcID protein was further purified using 5 mL Source S HiTrap column using the 
AKTA pure FPLC chromatography system. The column was equilibrated with Source S buffer A 
(50mM phosphate, pH 7.2) then the diluted sample was loaded onto the column. Next, the column 
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was washed with 5 column volumes of Buffer A. Next, the protein was eluted with high 
concentration of sodium ions as the column was washed with 10 column volumes over a 
concentration gradient of 0-100% Buffer B (50 mM phosphate, 1M sodium chloride, pH 7.2). The 
fractions were collected and analyzed via SDS-PAGE using a 12% acrylamide gel. The pure 
fractions were then combined and 1 mM DTT was added then buffer exchanged in storage buffer 
(10mM phosphate, 100mM sodium chloride, 10% glycerol, 1 mM DTT, pH 6.8) overnight. The 
protein was concentrated and stored in 150 µL aliquots at 100-200 µM concentrations at -80 °C. 
Protein concentrations were determined using UV-Vis spectroscopy with the extinction 
coefficient, ε = 22550 M-1cm-1 and mass confirmation was carried out by electrospray mass 
spectrometry. 
Peptide Synthesis  
Peptide synthesis was carried out using conventional solid phase peptide synthesis and microwave 
assisted peptide synthesis (CEM Liberty Blue).  
Peptides were synthesized on 50 µmole scale using CEM rink-amide resin (0.19-0.21 meq). The 
synthesis was carried out with dimethylformamide as the main solvent. Fmoc-amino acid 
concentrations were made to be 0.2M, deprotection solution was made up containing 20% 
piperidine, 0.2M Oxyma Pure. Diisopropylcarbodiimide (DIC) was the activator acid and Oxyma 
Pure was the activator base. The amino acids were coupled using 4-minute single coupling for 
peptide sequences shorter than 20 amino acids. The peptides were cleaved with 95% TFA:2.5% 
TIPS: 2.5% H2O. Excess cleavage cocktail was evaporated using nitrogen gas flow. The resulting 
solution was treated with cold diethyl ether then centrifuged to collect the peptide precipitate. The 
ether was decanted, and the pellet was redissolved in 30% 0.1% TFA/H2O and acetonitrile and 
lyophilized before purification. Peptides were redissolved in minimal acetonitrile (25%) and 0.1% 
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TFA/H2O solution and purified using reverse-phase HPLC (Agilent) with C-18 columns and 
0.1%TFA/H2O-acetonitrile solvent system. The purified fractions were collected and analyzed 
using mass spectrometry. These pure fractions were combined after identifying through mass 
spectrometry and lyophilized until a dry powder was left.  
The peptide was dissolved in DMSO. A sample of the DMSO was diluted 1:1000 in storage buffer 
to ascertain the concentration. Using UV-Vis, the concentration was measured at λ=495 nm for 
the FITC and an extinction coefficient, ε=72,000 M-1cm-1. Unlabeled peptides were weighed, and 
concentration determined. 
 
Manual Peptide Synthesis 
Peptides were synthesized using CLEAR amide resin (Peptide International) or rink amide resin 
(CEM). Manual synthesis reagents for CLEAR rink amide resin were HOBT, HBTU and DIPEA 
and that for CEM rink amide was DIC and HOBT. The first amino acids were coupled for a 
minimum of six hours followed by 2 hours of amino acid coupling up to the 10th residue and 
subsequently 2.5 hours beyond 10 residues. After the completion of the sequence, the N-terminus 
was deprotected. For fluorescein labeling, beta alanine was coupled to the N-terminus and then 2 
eq fluorescein isothiocyanate was coupled in the presence of 4 eq DIPEA. The N-terminus was 
acetylated for unlabeled peptide using 50 eq acetic anhydride and 50 eq DIPEA. 
The peptides were cleaved with 95% TFA:2.5% TIPS: 2.5% H2O. Excess cleavage cocktail was 
evaporated using nitrogen gas flow. The resulting solution was treated with cold diethyl ether then 
centrifuged to collect the peptide precipitate. The ether was decanted, and the pellet was 
redissolved in 30% 0.1% TFA/H2O and acetonitrile and lyophilized before purification. Peptides 
were redissolved in minimal acetonitrile (25%) and 0.1% TFA/H2O solution and purified using 
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reverse-phase HPLC (Agilent) with C-18 columns and 0.1%TFA/H2O-acetonitrile solvent system. 
The purified fractions were collected and analyzed using mass spectrometry. These pure fractions 
were combined after identifying through mass spectrometry and lyophilized until a dry powder 
was left.  
The peptide was dissolved in DMSO. A sample of the DMSO was diluted 1:1000 in storage buffer 
to ascertain the concentration. Using UV-Vis, the concentration was measured at λ=495 nm for 
the FITC and an extinction coefficient, ε=72,000 M-1cm-1. Unlabeled peptides were weighed, and 
concentration determined by what method? 
 
Peptoid Synthesis  
Peptoid synthesis was carried out using conventional solid phase peptide synthesis and microwave 
assisted peptide synthesis (CEM Liberty Blue).  
Peptoids were synthesized on 50 µmole scale using CEM rink-amide resin (0.19-0.21 meq). The 
synthesis was carried out with dimethylformamide as the main solvent. Bromoacetic acid 
concentration was made to be 2M, deprotection solution was made up containing 20% piperidine, 
0.2M Oxyma Pure to be used to deprotect Fmoc on amide resin and Fmoc-β-alanine. 2M 
Diisopropylcarbodiimide (DIC) was used as the coupling reagent for bromoacetic acid. The amines 
were made in 1M solutions and coupled using 4-minute single coupling. The peptoids were cleaved 
with 95% TFA:2.5% TIPS: 2.5% H2O. Excess cleavage cocktail was evaporated using nitrogen 
gas flow. The resulting solution was treated with cold diethyl ether then centrifuged to collect the 
peptide precipitate. The ether was decanted, and the pellet was redissolved in 30% 0.1% TFA/H2O 
and acetonitrile and lyophilized before purification. Peptides were redissolved in minimal 
acetonitrile (25%) and 0.1% TFA/H2O solution and purified using reverse-phase HPLC (Agilent) 
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with C-18 columns and 0.1%TFA/H2O-acetonitrile solvent system. The purified fractions were 
collected and analyzed using mass spectrometry. These pure fractions were combined after 
identifying through mass spectrometry and lyophilized until a dry powder was left.  
The peptoid was dissolved in DMSO. A sample of the DMSO was diluted 1:1000 in storage buffer 
to ascertain the concentration. Using UV-Vis, the concentration was measured at λ=495 nm for 
the FITC and an extinction coefficient, ε=72,000 M-1cm-1. Unlabeled peptoids were weighed, and 
concentration determined by what method. 
 
 
Fluorescence Polarization  
Fluorescence polarization direct binding assays were done in triplicate with a final volume of 20 
µL in a low volume, non-binding, 384-well black plate (Corning). Fluorescein-labeled DMSO 
peptide stocks were diluted to 50 nM using assay buffer (5 mM HNa2PO4, 5 mM NaH2PO4, 100 
mM sodium chloride, 10 % glycerol, pH 6.8). 10 µL of Med25 AcID was serially diluted two-fold 
going down the column of the 384-well plate using the assay buffer (10 µL assay buffer was placed 
in each well). No protein was added to the last row as it was a negative control with peptide only. 
Finally, 10 µL of peptide was added to each well to provide a final peptide concentration of 25 nM 
and the resulting mixtures left to incubate at room temperature for 30 minutes. After 30 minutes, 
the fluorescence polarization was measured using Tecan Genios Pro or PHERAstar plate reader 
(polarized excitation at 485 nm and emission intensity measured through a parallel and perpendicularly 
polarized 535 nm filter). Data was analyzed by binding isotherm that accounts for liganddepletion 
(assuming a 1:1 binding model of peptide to ACID) was fit to the observed 
polarization values as a function of AcID to obtain the equilibrium dissociation, 
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Kd. Each data point is an average of the triplicate experiments from each peptide with Med25 AcID 
and the error for standard deviation. “a” and “x” are the total concentrations of fluorescent peptide and 
Acid, respectively, “y” is the observed anisotropy at a given AcID concentration, “b” is the maximum 
observed anisotropy value, and “c” is the minimum observed anisotropy value.  
𝑦 = 𝑐 + (𝑏 − 𝑐) 𝑋 
(𝐾𝐷 + 𝑎 + 𝑥) − [√(𝐾𝐷 + 𝑎 + 𝑥)
2 − 4𝑎𝑥]
2𝑎




Circular Dichroism (CD) spectra of Med25 was obtained using J-715 spectropolarimeter (Jasco 
Inc) using a 1mm path length quartz cuvette. The peptoids were dissolved in acetonitrile (Toshiaki 
Hara et al) as they were insoluble in water. The spectra were measured from 260-180 nm at 1 nm 
increments at 200 nm/minute. A baseline spectrum was obtained using acetonitrile only followed 
by measurement of peptoids at 60 µM. The background spectra were subtracted from that of the 
peptoid before converting to mean residue ellipticity, θ using the following equation, where ψ = is 
the cd signal in degrees, n is the number of residues, l is the path length on centimeters and c is the 
concentration of the protein/peptide decimoles per cm3. 
[𝜃] =
𝜓
1000 ∗ 𝑛 ∗ 𝑙 ∗ 𝑐
 
 
Permeability Assay for CPP-Peptoids 
Dishes were pre-equilibrated by incubating 15 mm CELL-NEST dishes with 10% FBS DMEM. 2 
ml of medium were pipetted the dishes then placed in the incubator for 15 minutes. The VARI-
068 cells were passaged, counted, and suspended in 10% FBS DMEM. The cell culture medium 
was aspirated from the dish and cells were plated on the glass surface. 500 µl of cell suspension 
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was pipetted into 15 mm microwells. The cells were suspended in 35 mm culture dishes at 3 X 105 
cells per well. The dishes were subsequently incubated for 1 hour at 37 °C. After 1 hour the 
remainder of the dishes were filled with medium.  2 ml of medium was added to the 35 mm dishes 
then incubated for 24 Hours. The medium was aspirated after 24 hours then 500µL of 1% 
FBS/DMEM and 1 uL of peptoid for a final concentration of 5µM was added. The cells were 
incubated for 3 and 6 hours.  
The medium was removed after 1 hour and dished were washed with PBS 3 times. Cells were then 
fixed with 4% paraformaldehyde solution in PBS for 15 minutes at 37 °C The dishes were washed 
three times with PBS to remove non-specific binding. The cells were then treated with DAPI for 
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Protein-protein interactions (PPIs) are vital for the regular functioning of cellular systems. These 
interactions are the hallmarks of the transcription, which involves many proteins interacting in 
complex networks.1 There are several areas where abnormalities can occur in the PPI network and 
can result in diseases. 2Some of the most vital proteins involved in the transcription process are 
activators and coactivators. Activators have at minimum a DNA binding domain that binds to 
specific DNA sequences and a transcriptional activation domain (TAD) that recruits coactivators. 
The coactivators are large proteins that are often a part of larger coactivator hub complexes such 
as Mediator. Domains of the coactivators interacting with the TAD, activator-binding domains or 
ABDs, often bear large surface areas for PPIs without defined binding sites, thus making them 
challenging therapeutic targets.3 Additionally, the transient interactions of these PPIs serve as a 
challenge to better understand the mechanisms. Nonetheless, some progress has been achieved by 
using kinetic tools to measure the time of interactions and provide data to predict conformations 
of the complexes formed.4 
Despite the recent successes in the discovery of PPI-targeting small molecules, the same success 
has not been seen with activator-coactivator interactions due to the large surface area of the binding 
interfaces. As a result of these limitations, designing molecules for targeting these PPIs can be a 
daunting task. Hence, my strategy turned to designing molecules that can cover a larger surface 
84 
 
area by constructing mimics from the structure of  the native TADs that can be more 
conformationally dynamic and more biologically robust.5 
This work sought to identify the minimal binding sequences for the coactivator by identifying PPIs 
between identified TADs for the coactivators Med25 AcID. Previous work has proposed a 
structure for Med25 AcID that is structurally unique in comparison to other coactivators that are 
usually composed of the primarily a-helical structures.6 Two distinct binding surfaces on Med25 
AcID interact with specific TADs and the binding surfaces are denoted as H1 and H2. They   are 
located on the opposite faces of the protein (Figure 4.1). 
 
Figure 4.1 The AcID motif of the coactivator Med25 has two binding surfaces to interact with activators. These 
binding surfaces are denoted H1 and H2. This figure is adapted from  and created by Amanda Peiffer. 
 
The studies of Chapter Two confirmed that Med25 AcID interacts with three different activators 
despite the different sequences of each (Figure 4.1). Also, we confirmed that Med25 AcID binding 
surfaces show specificity for different TADs as demonstrated by mutations at the H1 and H2 
surfaces that differentially affect the TADs.7–9 Through experiments done by us and others, it was 
shown that ERM interacts with AcID in the H1 face. Mutations of three residues in the H1 face 
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affected binding of the ERM TAD by 3-6-fold. This did not affect the ATF6α TAD as it was 
known to interacts with H2 face of the coactivator.4  
To identify the minimal sequences needed for binding to Med25, VP16 was truncated in three 
equal sections. Additionally, two sequences were synthesized based on the location of the putative 
α-helices. These sets of data, obtained by Dr. Steve Sturlis, suggest that we were able to design 
minimal sequences from the largest TAD to obtain low micromolar affinity. From this information, 
I demonstrated that we could reduce the sequences to even lower number VP16 472-479 has been 
shown to minimal activate transcription. This is an 8-residue peptide  that is in the C-terminal 
domain of VP16 TAD. The direct binding was measured and produced a low micromolar affinity 
for Med25 AcID. The results of this suggest that we can use this to understand binding to Med25 
AcID and to design peptidomimetics.  Based on these results, I identified an octamer of similar 
sequence located in ATF6α that also binds to the H2 face Med25 with a sub-micromolar affinity.  
In Chapter Three we showed that we synthesized peptoids mimicking minimal sequences 
identified in Chapter two. These were synthesized on solid support using amines mimicking the 
side chains of the parent peptides. We demonstrated that these can be mimicked and recapitulate 
binding to Med 25 AcID. We also addressed the question of specificity by comparing the binding 
to the CBP-KIX coactivator. The peptoids retained specificity for the target protein, thus allowing 
us to further address questions such as ability to improve the binding. These were done by 
extending the sequence with the surrounding residues.  
We later sought to answer the question of cell permeability. We used the HIV-1 TAT49-57 as the 
cell penetrating peptide to append to the modified peptoid.10–14 Some of the preliminary work 
illustrates that we can deliver mimicked TADs into cells. The ability for us to deliver these are 
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promising with the evidence we have garnered; we will seek to deliver peptoids of known TADs 
to create potent inhibitors. 
 
4.2 Future Directions 
The use of peptidomimetics for the development of effective activator•coactivator inhibitors hold 
great promise based on what has been established in this work and previous work of others. These 
peptoids hold great promise because they are comparable to small molecules inhibitors reported in 
previous studies. As can be gleaned from this dissertation, peptoids were developed with low 
micromolar affinities for the coactivator Med25 AcID. One example is the small molecule 
compound MS120/Ischemin, which has been an effective inhibitor of the CREB-p53 PPI despite 
having an affinity of 19 µM.15,16 This is close to the affinities I have reported in the previous 
chapters. Therefore, this shows that these synthetic molecules reported earlier are promising 
synthetic molecules for successfully targeting coactivator-activator PPIs. 
One other example of small molecule with affinity similar to peptoids reported in this dissertation 
is KG-501, which inhibits CBP-CREB interaction, and has an affinity for CBP of 50µM, a direct 
affinity up to 15-fold lower that what is described here. The third example is compound 2 
(10074A4) with a Kd of ~5 µM, which is similarly a low micromolar affinity compound. Like the 
two small molecules mentioned earlier, this has successfully inhibited the c-Myc-Max 
interaction.17  
With these similar numbers, these studies have established that despite not having a submicromolar 
affinity for their target proteins, they can successfully inhibit the PPI of coactivators and their 
binding partners.  
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 Peptoids are dynamic mimetics that can be modified and synthesized with ease and are very cost-
efficient. These allow for the testing and designing of diverse molecules that are capable of 
interacting with larger surface areas. By identifying the components of native TADs, these can be 
designed to create a lead compound that can be easily modified to improve potency. With the 
number of amines available, this allows for larger library creations with diverse functional groups. 
Lead compounds can be identified using traditional library synthesis and screenings. In creating 
these large number of compounds this allows us to modify leads to improve the activities. As a 
result, this helps to better design these compounds and possible incorporate unnatural side chains 
to improve potency.  
Following the identification of molecules, we can modify these and compare their activities by 
synthesizing both linear and cyclic versions of these molecules.  Past studies have utilized cyclic 
versions of peptides to improve permeability as they are delivered to the sites. As recent as 2017, 
the Unites States Food and Drug Administration approved plecanatide, which is a cyclic peptide 
used to treat idiopathic constipation.18 We will be able to develop the potent molecules with 
inspirations from various molecules that have successfully been developed. 
As we understand more about the interactions, we hope to identify key components of other TADs 
that can help us to better understand how we can leverage the characteristics of peptoids to improve 
activities of the peptoids. We hope to use various mammalian systems and study the effect that 
these will have on toxicity as we improve the use of CPPs.19 
By using many techniques to create a large toolbox and create a design consensus, we hope to 
better design peptidomimetics with improved activities. This can help us to better understand wider 
activator-coactivator interactions by obtaining information at a rapid rate and develop efficiency 
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of our designs. We will be able to produce more naturally occurring peptides and peptidomimetics 
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Characterization of synthesized peptides and peptoids 
The appendix contains the analytical chromatograms and mass spectrometry of the peptide and 
peptoids used in the fluorescence polarization assays and cell-penetrations studies throughout 
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Mass spectrometry of peptides and peptoids used throughout this thesis. 
 
 
Peptoid 1 (m/z = 1087.50) 
 
 
Peptoid 2 (m/z = 1129.53) 
 
 





Peptoid 4 (m/z = 3499.61) 
 
 
Peptoid 5 (m/z = 2489.20) 
 
 
Peptoid 6 (m/z = 2555.20) 
 
 
ATF6α VN8 Peptide (m/z = 1405.55) 
 
 







Peptoid 7 (m/z = 1514.81) 
 
Peptoid 8 (m/z = 1509.82) 
 
Peptoid 9 (m/z= 1563.86) 
 
Peptoid 10 (m/2 = 1415.83) 
 
 
